Incyte management check
INCY · Health Care · Biotechnology · CEO William Meury
Filings as of
Closest peers in Biotechnology
- 38GILDGilead Sciences83
- 50VRTXVertex Pharmaceuticals81
- 88REGNRegeneron Pharmaceuticals77
- 111AMGNAmgen76
- 208ABBVAbbVie68
- 300INCYIncyte61
- 405MRNAModerna53
- 439BIIBBiogen48
The seven checks
- WatchTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
4349thDetail
$100 invested at the start of fiscal 2021 grew to $114, against $120 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9274thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.85 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch2.5% of net income
What does the CEO cost owners?
$32.1m pay · $1.3bn net income, FY2025
1723rdDetail
$32.1m of reported pay in fiscal 2025, against $1.3bn of net income.
- n/aNo recent CEO filing
Do they own the stock?
——Light activity: no buys, $49.2m sold in six months. 39 of 39 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −5.7% a year; flagged above +2%
Stock pay 4.8% of revenue
100100thDetail
Diluted shares changed -5.7% a year over the last three fiscal years. Stock-based pay was 4.8% of revenue in the latest year.
- Watch2 CEOs in the pay table
Is leadership stable?
8 filings under 8-K 5.02 in 3 years
CEOs: Mr. Hoppenot, Mr. Meury
4521stDetail
CEOs in the pay table: Mr. Hoppenot, Mr. Meury. 8 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- WatchAn annual report was amended
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 110-K amended
7015thDetail
No restatements, auditor changes or late filings since 2021. 1 amended annual report.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 28, 2026.
Pay tied most to total product revenues
Other key measuresTotal product revenuesPipeline development and progressionTotal shareholder return (TSR)
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Mr. Hoppenot, Mr. Meury | $32.1m | $54.7m | $6.3m | $114 | $120 | $1.3bn |
| 2024 | Mr. Hoppenot | $17.5m | $25.2m | $5.9m | $79 | $91 | $32.6m |
| 2023 | Mr. Hoppenot | $16.7m | $7.8m | $7.8m | $72 | $92 | $597.6m |
| 2022 | Mr. Hoppenot | $16.7m | $16.0m | $5.8m | $92 | $89 | $340.7m |
| 2021 | Mr. Hoppenot | $14.4m | $6.2m | $5.2m | $84 | $99 | $948.6m |
Insiders and the CEO's stakeQuiet
- Chief Executive Officer
- William Meury
- Shares held
- 183,129
- Latest Form 4
- Jul 16, 2026
Light activity: no buys, $49.2m sold in six months. 39 of 39 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldSteven H SteinCMO & Head of Late-Stage Dev. · 10b5-1 plan$31.9mNov 16, 2026
- SoldPablo J CagnoniPresident, Global Head of R&D · 10b5-1 plan$9.3mNov 16, 2026
- SoldPatrick A MayesEVP & Chief Scientific Officer · 10b5-1 plan$6.0mAug 5, 2026
- SoldLee HeesonEVP, Head of Incyte Intl · 10b5-1 plan$1.3mNov 13, 2026
Leadership and governance on file
All 14 filings
- Mar 30, 2026Leadership change8-K 5.02
- Mar 26, 2026Leadership change8-K 5.02
- Dec 12, 2025Leadership change8-K 5.02
- Oct 3, 2025Leadership change8-K 5.02
- Aug 7, 2025Leadership change8-K 5.02
- Jun 27, 2025Leadership change8-K 5.02
- Jun 11, 2025Leadership change8-K 5.02
- Jan 10, 2025Leadership change8-K 5.02
- Feb 16, 2024Annual report amended10-K/A
- Sep 12, 2023Leadership change8-K 5.02
- Jun 15, 2023Leadership change8-K 5.02
- Oct 4, 2022Leadership change8-K 5.02
- Apr 21, 2022Leadership change8-K 5.02
- Jan 14, 2022Leadership change8-K 5.02
Latest shareholder vote results: Jun 9, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $2.0bn returned to owners in buybacks and dividends, 63% of net income, and $1.1bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.0bn | $3.4bn | $3.7bn | $4.2bn | $5.1bn |
| Net income | $948.6m | $340.7m | $597.6m | $32.6m | $1.3bn |
| Stock-based pay | $183.0m | $188.4m | $215.9m | $266.1m | $249.3m |
| Buybacks | — | $0 | $0 | $2.0bn | $0 |
| Dividends | — | — | — | — | — |
| Diluted shares | 222m | 224m | 226m | 211m | 201m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.